Thursday, March 17, 2011

Astellas to buy out Maxygen interest in joint venture for $76 million

Astellas Pharma Inc. will buy out Maxygen Inc.’s interest in Redwood City joint venture Perseid Therapeutics Inc. for $76 million.
Astellas and Maxygen (NASDAQ: MAXY) of Redwood City set up the joint venture in summer 2009, with Maxygen transferring substantially all of its protein pharmaceutical programs and related assets and R&D personnel to Perseid. It granted Astellas an option to to buy all of Maxygen’s ownership interest in Perseid at exercise prices that increased each quarter until Sept. 18, 2012.

No comments:

Post a Comment